A blood test that can scan for signals from up to 50 different cancer types in a single vial of blood is now under formal FDA review. GRAIL, Inc. submitted the final module of its Premarket Approval application to the FDA in January 2026 for its Galleri multi-cancer early detection test, marking the most advanced regulatory step yet toward routine clinical use of what the company and many oncologists consider a potentially transformative screening tool.
If the FDA approves the test, it could reshape how the United States approaches cancer screening for adults over 50 — and could eventually be covered by Medicare as early as 2028, according to GRAIL's president.
Why This Matters
Cancer is the leading cause of death in U.S. adults over 50, according to GRAIL President Josh Ofman, MD. And most deadly cancers share a disturbing common thread: they are discovered late, when treatment options are limited, and outcomes are significantly worse.
Current cancer screening is largely disease-specific. A colonoscopy looks for colorectal cancer. A mammogram screens for breast cancer. A low-dose CT scan screens for lung cancer in high-risk individuals. Each screening requires a separate test, a separate appointment, and separate insurance coverage decisions. More importantly, many of the cancers most likely to kill — including pancreatic, ovarian, and liver cancer — have no widely recommended screening test at all.
Galleri is designed to change that by detecting chemical changes in cell-free DNA that leak from tumors into the bloodstream — a process that can identify cancer signals from dozens of different tumor types in a single sample.
What We Know So Far
According to GRAIL's January 2026 press release, the PMA submission is supported by data from two large studies: the U.S.-based PATHFINDER 2 study, which enrolled 25,490 participants, and the NHS-Galleri trial, which enrolled more than 140,000 asymptomatic participants aged 50 to 77 across England — the largest randomized controlled trial ever conducted to assess the clinical utility of a multi-cancer early detection test for population screening.
The FDA designated Galleri as a Breakthrough Device in 2018. The test has been commercially available as a laboratory-developed test since 2021, with more than 475,000 tests sold, but FDA approval would clear the way for broader insurance coverage, including the possibility of Medicare reimbursement.
NPR reported on June 22, 2026 that FDA approval could come as early as late 2026, potentially setting the stage for Medicare coverage starting in 2028.
Where the Impact Would Be Greatest
The test is designed for asymptomatic adults over 50 who have no clinical suspicion of cancer — exactly the population in whom early detection would offer the greatest survival benefit. This includes the tens of millions of Americans who are not currently eligible for any cancer screening test other than mammography or colorectal cancer screening.
Communities with limited access to specialty cancer care — including rural populations in the South, the Appalachian region, and parts of the Midwest — stand to benefit most from a primary care-ordered blood test that does not require a specialist referral or a dedicated screening procedure.
Major urban centers with large populations of older adults — including New York, Chicago, Houston, Phoenix, and Los Angeles — would also see significant demand if the test receives broad insurance coverage.
What Doctors and Experts Say
"Cancer is now the leading killer of adults over 50 years old in the U.S., and most deadly cancers are often discovered too late, when they are difficult to treat and typically have worse outcomes," Dr. Ofman said. "Adding Galleri to standard-of-care single cancer screening tests has the potential to dramatically improve the performance of the nation's current screening program."
Clinical researchers in the NHS-Galleri trial and PATHFINDER 2 study have noted that the test is intended to complement — not replace — existing single-cancer screening tools. Patients who receive a cancer-signal-detected result undergo additional diagnostic testing to identify the cancer type and stage. The test is not a diagnosis; it is a signal requiring follow-up.
What the Evidence Shows — and What It Does Not
The PATHFINDER 2 study results demonstrate the test's safety and performance across multiple measures, including positive predictive value (what percentage of cancer-signal-detected results are confirmed cancers), negative predictive value, sensitivity, and specificity. Results from the NHS-Galleri trial's primary objective — showing a reduction in late-stage cancers in people who received the Galleri test — are being evaluated as part of the PMA submission.
Clinical data from Galleri's earlier work, cited by GRAIL and covered in previous peer review, found that more than half of cancers identified were caught in early stages when treatment is most effective.
MedicalDaily Evidence Check
- Study type: Registrational prospective study (PATHFINDER 2) + largest ever prospective randomized controlled trial (NHS-Galleri, 140,000+ participants)
- Key performance metrics: PPV, NPV, sensitivity, specificity, cancer signal origin (tumor type prediction)
- What it found: Signals from up to 50 cancer types detectable from a single blood sample; early-stage detection in more than half of cancer-signal-detected cases in prior studies
- What it has not yet proven: Whether routine population-level screening with Galleri reduces cancer mortality (the NHS-Galleri trial's primary endpoint, results pending)
- Current status: Under FDA premarket approval review, designated Breakthrough Device
Who Faces the Greatest Risk?
The test is intended for adults 50 and older with no symptoms and no clinical suspicion of cancer. People in this group who are not already receiving recommended screenings for colorectal, breast, cervical, or lung cancer are among those who would benefit most. Individuals with a family history of multiple cancers, those who have not been offered or have not completed recommended screenings, and those whose cancer type has no existing screening option face the greatest potential benefit from a multi-cancer detection approach.
What You Can Do Now
- The Galleri test is already available as a laboratory-developed test and can be ordered by a physician today, though it is not yet covered by Medicare or most commercial insurers. The current cash price is roughly $949.
- If you are over 50, discuss your current cancer screening status with your physician, including whether you are up to date on colorectal, lung, and breast cancer screening per current guidelines.
- Monitor FDA announcements. If the agency approves the test in late 2026, coverage decisions are expected to follow from major insurers and Medicare in 2027–2028.
- Do not stop existing recommended cancer screenings while waiting for an FDA decision on Galleri. Colonoscopy, mammography, and low-dose CT lung screening remain the gold standard for their respective cancers.
Cost and Access: What Patients Should Know
As of mid-2026, Galleri is not covered by Medicare or most commercial health insurance plans. GRAIL has said that FDA approval is expected to be a key trigger for insurance coverage decisions. The company's president has stated that approval would enable Medicare coverage to begin in 2028. Patients who want to access the test now would pay out of pocket.
GRAIL also sells Galleri through employer health plans in some markets. Patients should ask their employer's benefits coordinator whether the test is included in their plan.
What Happens Next
The FDA is actively reviewing GRAIL's PMA application. The agency has designated Galleri a Breakthrough Device, which entitles it to more intensive FDA guidance and priority review. No PDUFA date has been publicly announced, but media reports suggest a decision could come in late 2026. If approved, it would mark the first FDA-authorized multi-cancer early detection test in the United States. The NHS-Galleri trial's primary endpoint results — the mortality reduction data — are expected to add further evidence in the coming years. MedicalDaily will report on the FDA's decision when it is announced.
The Bottom Line
The Galleri blood test represents one of the most significant potential advances in cancer screening in decades. Its FDA approval is being considered now, with a possible decision by late 2026. For adults over 50, the test offers the possibility of detecting cancers that currently have no screening option, potentially earlier in their course, when outcomes are significantly better. Until the FDA rules and insurance coverage follows, patients should continue all currently recommended screenings and talk to their doctor about whether early access to Galleri makes sense for their situation.
